Biotechnology Companies By Operating Cash Flow

Cash Flow From Operations
Cash Flow From OperationsEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
22.84 B
 0.03 
 1.35 
 0.04 
2AMGN Amgen Inc
8.47 B
 0.03 
 1.36 
 0.05 
3GILD Gilead Sciences
8.01 B
 0.04 
 1.44 
 0.05 
4GMAB Genmab AS
7.38 B
 0.00 
 2.09 
(0.01)
5BNTX BioNTech SE
5.35 B
(0.02)
 2.88 
(0.06)
6REGN Regeneron Pharmaceuticals
4.59 B
 0.05 
 1.82 
 0.09 
7VRTX Vertex Pharmaceuticals
3.54 B
 0.07 
 1.77 
 0.13 
8HLN Haleon Plc
2.06 B
 0.03 
 1.67 
 0.05 
9BIIB Biogen Inc
1.55 B
 0.02 
 2.45 
 0.05 
10UTHR United Therapeutics
978 M
 0.04 
 1.77 
 0.07 
11INCY Incyte
496.49 M
(0.02)
 1.62 
(0.03)
12ALKS Alkermes Plc
401.35 M
 0.03 
 2.31 
 0.07 
13NBIX Neurocrine Biosciences
389.9 M
 0.05 
 1.82 
 0.09 
14HALO Halozyme Therapeutics
388.57 M
 0.02 
 2.49 
 0.06 
15EXEL Exelixis
333.32 M
 0.02 
 1.99 
 0.03 
16ACLX Arcellx
207.57 M
 0.08 
 4.66 
 0.39 
17ZYME Zymeworks Common Stock
195.1 M
 0.05 
 4.53 
 0.24 
18IRWD Ironwood Pharmaceuticals
183.43 M
 0.00 
 2.73 
 0.00 
19BMRN Biomarin Pharmaceutical
159.26 M
 0.02 
 1.97 
 0.04 
20EXAS EXACT Sciences
156.12 M
 0.02 
 3.76 
 0.07 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings. Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.